Clinical Trials Logo

Allergic Contact Dermatitis clinical trials

View clinical trials related to Allergic Contact Dermatitis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05339750 Completed - Clinical trials for Allergic Contact Dermatitis

Allergy Skin Patch Artificial Intelligence (AI)

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to assess human and artificial intelligence performance in grading contact dermatitis reactions in healthy volunteers.

NCT ID: NCT04365140 Completed - Clinical trials for Allergic Contact Dermatitis

MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel

Start date: March 1, 2019
Phase:
Study type: Observational [Patient Registry]

Background. Allergic Contact Dermatitis (ACD) is an inflammatory skin disease mediated by direct contact with allergens as nickel, the most common allergen, that may be related with epigenetic changes. Objective. Evaluate the miR-126 expression and its target VCAM-1, in the skin of patients with ACD to nickel. Methods. Fifteen patients with positive patch test to nickel were included, and the expression of miR-126 and VCAM-1 was evaluated by RT-qPCR.

NCT ID: NCT03945760 Completed - Clinical trials for Allergic Contact Dermatitis

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Start date: September 14, 2020
Phase: Early Phase 1
Study type: Interventional

The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hypersensitivity (allergic) versus Irritant Skin reactions. Subjects for this study need to be healthy males between the ages of 18 and 40. This study will evaluate this by injecting antigens as well as applying them on top of the skin to the forearm then measure the effects of Baricitinib by skin and blood testing.

NCT ID: NCT03902392 Completed - Clinical trials for Allergic Contact Dermatitis

Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis

Grapolyphen
Start date: April 16, 2018
Phase: N/A
Study type: Interventional

Nickel (Ni)-mediated allergic contact dermatitis (ACD) is a very common disease worldwide. Our previous findings demonstrated that in vitro supplementation of polyphenols, extracted from seeds of red grape (Nero di Troia cultivar), to peripheral lymphomonocytes from Ni-mediated ACD patients could reduce release of T helper (h)1 [interferon (IFN)-] and Th2 [interleukin (IL)-4] cytokines, on the one hand. On the other hand, IL-10 (an anti-inflammatory cytokine) levels increased with a reduction of IL-17 (an inflammatory cytokine). Also levels of nitric oxide (NO) decreased in response to polyphenol pretreatment.

NCT ID: NCT02534441 Completed - Clinical trials for Allergic Contact Dermatitis

Epidemiology and Co-Reactivity of Novel Surfactant Allergens

Start date: August 2015
Phase: N/A
Study type: Interventional

The primary objectives of this study are to identify positivity rates to three novel surfactants (ingredients used in soaps, detergents, and other cleansers that serve to lower the surface tension of the skin and remove debris) and co-reactivity with other surfactants in patients with known surfactant sensitivity on skin patch testing. The investigators hypothesize that subjects who previously tested positive to known allergenic surfactants (cocamidopropyl betaine, stearamidopropyl dimethylamine, dimethylaminopropylamine, coconut diethanolamide, oleamidopropyl dimethylamine, and decyl glucoside) may demonstrate co-reactivity to the three novel surfactant sensitizers (sodium lauroyl sarcosinate, isostearmidopropyl morpholine lactate, and disodium lauroamphodiacetate) on skin patch testing.

NCT ID: NCT01798589 Completed - Clinical trials for Allergic Contact Dermatitis

Bioequivalence of Ethylenediamine Dihydrochloride Study

Start date: July 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.

NCT ID: NCT01797562 Completed - Clinical trials for Allergic Contact Dermatitis

Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents

Start date: December 10, 2012
Phase: N/A
Study type: Interventional

The objective of the study was to evaluate the diagnostic performance and safety of T.R.U.E. Test allergens in pediatric subjects aged 6-17 years old. In total, 11 allergens were evaluated; 7 new allergens on panels 2.2 and 3.2 and 4 previously approved allergens for which changes were made to dose and excipient.

NCT ID: NCT01546298 Completed - Clinical trials for Allergic Contact Dermatitis

Immune Reactions in Contact Dermatitis Affected Skin

Start date: January 2012
Phase:
Study type: Observational

This study hopes to improve the investigators understanding of how the immune system acts in allergic contact dermatitis. In order to reach this goal, normal volunteers, who are suspected of having allergic contact dermatitis, will be patch tested for the fifteen most common allergens. Then, biopsies will be taken of the skin at the sites where the there is a positive reaction to the allergen. Also, small biopsies will be taken from an area that received a patch but no allergen and an area that did not receive a patch to serve as controls. In a second stage of the study, volunteers will receive patches with the allergen to which they demonstrated an allergic response. More biopsies will be taken, over three designated time points. The biopsied skin samples will then be studied in a laboratory.

NCT ID: NCT01244607 Completed - Clinical trials for Allergic Contact Dermatitis

NI-0801 in Allergic Contact Dermatitis

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the effect of a single dose of NI-0801 on the severity of nickel-induced allergic contact dermatitis.

NCT ID: NCT00931242 Completed - Atopic Dermatitis Clinical Trials

Study of Apremilast in Atopic or Contact Dermatitis

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy of apremilast in patients with recalcitrant atopic or contact dermatitis.